Correlation of EGFR, IDH1 and PTEN status with the outcome of patients with recurrent glioblastoma treated in a phase II clinical trial with the EGFR-blocking monoclonal antibody cetuximab
Shasha Lv(Molecular Oncology (United States)), Bart Neyns(Molecular Oncology (United States))
Cited by 64
Related Papers
No related papers found
Powered by citation graph analysis